For the past eight years, the CDD for Biologics Summit has united computational and structural biologists, along with protein ...

Unearthing novel targets for radiopharmaceuticals from ACP3m, AVB6, AVB8, and PDL-1 with Philochem, TRIMT, Fusion-AstraZeneca ...

The European Society for Medical Oncology (ESMO) 2024 meeting was a well-attended affair at the sprawling Fira Gran Via ...

The critical need to improve prior authorisation processes might have reached its tipping point on the 17th January. That’s ...

Apple has the FDA authorisation it needs to bring its software for detecting sleep apnoea to the Apple Watch, coinciding with ...

Finding oneself at an advanced stage of disease is devastating and may diminish one’s hope for the future. Participation in a ...

Ioannis Sapountzis, head of global therapeutic areas at Boehringer, said that FIBRONEER-IPF is the largest trial in IPF ...

Mid-stage data reported at the ESMO congress in Barcelona showed that ponsegromab was able to increase weight by 5.6% at the ...

Johnson & Johnson is planning a phase 3 programme for Rybrevant in colorectal cancer as a follow-up to its first indication ...

As a result, commercial teams are evolving as valuable partners to HCPs. From educating key experts before launch and ...

AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC) that it hopes will be enough to secure ...